Evidence map›Paper›PMID 33911008›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2021

Genome-Wide B Cell, CD4

Swayam Prakash, Ruchi Srivastava, Pierre-Gregoire Coulon, Nisha R Dhanushkodi, Aziz A Chentoufi, Delia F Tifrea, Robert A Edwards, Cesar J Figueroa, Sebastian D Schubl, Lanny Hsieh and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Broad beta-CoV immunity and transmission blockade by a single-dose live-attenuated vaccine with atypical codon usage.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Swayam PrakashLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, CA.
Ruchi SrivastavaLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, CA.
Pierre-Gregoire CoulonLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, CA.ORCID 0000-0001-6458-8710
Nisha R DhanushkodiLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, CA.
Aziz A ChentoufiLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, CA.ORCID 0000-0002-5410-2593
Delia F TifreaDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, CA.
Robert A EdwardsDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, CA.ORCID 0000-0001-9145-382X
Cesar J FigueroaDivision of Trauma, Burns, Critical Care, and Acute Care Surgery, Department of Surgery, School of Medicine, University of California Irvine, Irvine, CA.ORCID 0000-0001-5538-5698
Sebastian D SchublDivision of Trauma, Burns, Critical Care, and Acute Care Surgery, Department of Surgery, School of Medicine, University of California Irvine, Irvine, CA.
Lanny HsiehDivision of Infectious Diseases and Hospitalist Program, Department of Medicine, School of Medicine, University of California Irvine, Irvine, CA.
Michael J BuchmeierCenter for Virus Research, Division of Infectious Disease, School of Medicine, University of California Irvine, Irvine, CA.ORCID 0000-0002-2387-9287
Mohammed BouzianeSunomix Therapeutics, Inc., San Diego, CA; and.ORCID 0000-0003-2578-1280
Anthony B NesburnLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, CA.
Baruch D KuppermannLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, CA.
Lbachir BenMohamedLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California Irvine, Irvine, CA; Lbenmoha@uci.edu.
University of California, Irvine · USFate Therapeutics (United States) · US

Funding

Therapeutic Ocular HSV Vaccine in HLA Transgenic RabbitsR01EY019896 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2010 to 2025
$5.1M
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital HerpesR01AI150091 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Lbachir BenMohamed · 2020 to 2026
$4.0M
Developing a Multi-epitope Pan-Coronavirus VaccineR01AI158060 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2020 to 2024
$3.7M
Ocular Mucsoal Immunity Induced by HSV-1 LipopeptidesR01EY014900 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2003 to 2014
$3.1M
Mucosal Chemokines and CD8+ T Cell Immunity to Genital HerpesR01AI143348 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2022
$2.4M
Impact of Immune Checkpoints Blockade on HSV-1 Neuro-PathogenesisR21AI143326 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$464k
LAT-HVEM Interactions Effect HSV-1 Latency/ReactivationR21AI110902 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2015 to 2016
$425k
PROTECTIVE IMMUNITY AGAINST RECURRENT OCULAR HERPES INDUCED WITH SELF-ASSEMBLING PROTEIN NANOPARTICLESR21AI147499 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$399k
A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINER41AI138764 · NIAID · SUNOMIX THERAPEUTICS · PI BENMOHAMED, LBACHIR · 2018 to 2018
$236k
A NOVEL IMMUNO-PROTEOMIC APPROACH TO A GENITAL HERPES VACCINER43AI124911 · NIAID · IMMPORT THERAPEUTICS, INC. · PI LIANG, XIAOWU · 2016 to 2016
$225k
NEI NIH HHS R01 EY014900NEI NIH HHS R01 EY019896NIAID NIH HHS R01 AI143348NIAID NIH HHS R01 AI150091NIAID NIH HHS R01 AI158060NIAID NIH HHS R21 AI110902NIAID NIH HHS R21 AI143326NIAID NIH HHS R21 AI147499NIAID NIH HHS R41 AI138764NIAID NIH HHS R43 AI124911
6 · The paper itself

Abstract

Over the last two decades, there have been three deadly human outbreaks of coronaviruses (CoVs) caused by SARS-CoV, MERS-CoV, and SARS-CoV-2, which has caused the current COVID-19 global pandemic. All three deadly CoVs originated from bats and transmitted to humans via various intermediate animal reservoirs. It remains highly possible that other global COVID pandemics will emerge in the coming years caused by yet another spillover of a bat-derived SARS-like coronavirus (SL-CoV) into humans. Determining the Ag and the human B cells, CD4

Indexed as

Epitopes, T-LymphocyteMiddle East Respiratory Syndrome CoronavirusSARS-CoV-2Severe acute respiratory syndrome-related coronavirusAdultAgedAged, 80 and overAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleGenome, ViralGenome-Wide Association StudyHumansMaleMiddle AgedEpitopes, T-LymphocyteViral Vaccines

Identifiers

PMID33911008
PMCPMC8722450
OpenAlexW3157646192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.